USE OF GENE THERAPY TO INDUCE TRANSPLANT TOLERANCE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: Xenograft transplantation for patients with end-stage diseases represents a potential solution to the shortage of human organ donors. Humans reject grafts from porcine donors due to pre-existing natural xenoantibodies directed at the gal alpha1,3gal carbohydrate which is synthesized by alpha1,3-galactosyltransferase. This enzyme is not expressed in humans, apes, or old world monkeys. These species, therefore, produce xenoantibodies directed at the gal carbohydrate which is expressed on pig cells.